Kevin A. Juarez-Ornelas

Kevin A. Juarez-Ornelas

Auto-generated profile, based on publicly available information

Kevin A. Juarez-Ornelas

Davenport Research Laboratories, Department of Chemistry, University of Toronto

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in RSC Advances
Verified
Journal Article
Open access
PDF file
YSYuvraj Satkar
Yuvraj Satkar
VRVelayudham Ramadoss
Velayudham Ramadoss
PNPradip D. Nahide
Pradip D. Nahide
EGErnesto García-Medina
Ernesto García-Medina
KJKevin A. Juárez-Ornelas
Kevin A. Juárez-Ornelas
CSCésar R. Solorio-Alvarado
César R. Solorio-Alvarado
A practical electrophilic bromination procedure for the phenolic core was developed under efficient and very mild reaction conditions. The new I(iii)-based brominating reagent PhIOAcBr operationally easy to prepare by mixing PIDA and AlBr 3 was used.

12 February 2019 in Organic Letters
Verified
Journal Article
Closed access
KJKevin A. Juárez-Ornelas
Kevin A. Juárez-Ornelas
JJJ. Oscar C. Jiménez-Halla
J. Oscar C. Jiménez-Halla
TKTerumasa Kato
Terumasa Kato
CSCésar R. Solorio-Alvarado
César R. Solorio-Alvarado
KMKeiji Maruoka
Keiji Maruoka

24 January 2018 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
PNPradip D. Nahide
Pradip D. Nahide
VRVelayudham Ramadoss
Velayudham Ramadoss
KJKevin A. Juárez‐Ornelas
Kevin A. Juárez‐Ornelas
YSYuvraj Satkar
Yuvraj Satkar
RORafael Ortiz-Alvarado
Rafael Ortiz-Alvarado
CSCésar R. Solorio-Alvarado
César R. Solorio-Alvarado

27 October 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RHRachel Harding
Rachel Harding
RFRenato Ferreira de Freitas
Renato Ferreira de Freitas
PCPatrick Collins
Patrick Collins
IFIvan Franzoni
Ivan Franzoni
MRMani Ravichandran
Mani Ravichandran
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith

9 August 2016 in Arkivoc
Verified
Journal Article
Open access
VRVelayudham Ramadoss
Velayudham Ramadoss
PNPradip D. Nahide
Pradip D. Nahide
KJKevin A. Juárez-Ornelas
Kevin A. Juárez-Ornelas
MRMarvin Rentería-Gómez
Marvin Rentería-Gómez
RORafael Ortíz-Alvarado
Rafael Ortíz-Alvarado
CSCésar R. Solorio-Alvarado
César R. Solorio-Alvarado

22 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRachel Harding
Rachel Harding
IFIvan Franzoni
Ivan Franzoni
MMMandeep K. Mann
Mandeep K. Mann
MSMagdalena M. Szewczyk
Magdalena M. Szewczyk
BMBijan Mirabi
Bijan Mirabi
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Histone deacetylase 6 (HDAC6) inhibition is an attractive strategy for treating numerous cancers, and HDAC6 catalytic inhibitors are currently in clinical trials. The HDAC6 zinc-finger ubiquitin-binding domain (UBD) binds free C-terminal diglycine motifs of unanchored ubiquitin polymer chains and protein aggregates, playing an important role in autophagy and aggresome assembly. However, targeting this domain with small molecule antagonists remains an underdeveloped avenue of HDAC6-focused drug discovery. We report SGC-UBD253 (25), a chemical probe potently targeting HDAC6-UBD in vitro with selectivity over nine other UBDs, except for weak USP16 binding. In cells, 25 is an effective antagonist of HDAC6-UBD at 1 µM, with marked proteome-wide selectivity. We identified SGC-UBD253N ( 32 ), a methylated derivative of 25 which is 300-fold less active, serving as a negative control. Together, 25 and 32 could enable further exploration of the biological function of the HDAC6 UBD and investigation of the therapeutic potential of targeting this domain.